News Sentiment

OMER sentiment intelligence

Omeros Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 43 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.28 Week of 10 Jul 2026
Weighted tone 43/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+10.8% over one week, +17.7% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 10.8% Price confirming higher
Trend fit Trend inactive 17.7% over four weeks
Fair value 63.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 31
Negative 18

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 9
TradingView 7
simplywall.st 5
Stocktwits 4
Pluang 3
Investing.com 3
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 14
Regulatory and legal 12
Deals and strategy 3
Analyst action 2
Capital return 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Stock Traders Daily Direct company coverage

Understanding Momentum Shifts in (OMER)

Omeros Corporation (OMER) is experiencing weak near-term sentiment despite long-term strength, with its support levels currently being tested. AI models have generated three trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles, alon

Tone
Positive 63/100
Event
Market update
Published
15 Jul 2026 15:44
Source
Stock Traders Daily
Pluang Direct company coverage

Omeros stock drops 19% after EU rejects key drug application, prompting investor lawsuit.

Omeros Corporation's stock dropped 19.12% after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its drug narsoplimab. This rejection led to Pomerantz LLP launching a securities fraud investigation on behalf of Ome

Tone
Negative 10/100
Event
Regulatory and legal
Published
14 Jul 2026 22:42
Source
Pluang
GlobeNewswire Direct company coverage

Omeros Corporation Investigated by the Portnoy Law Firm

The Portnoy Law Firm has launched an investigation into Omeros Corporation (NASDAQ: OMER) for potential securities fraud and may file a class action lawsuit. This follows a significant 19.12% drop in Omeros's stock price after the European Medicines Agency's committee issued a ne

Tone
Negative 28/100
Event
Regulatory and legal
Published
13 Jul 2026 14:41
Source
GlobeNewswire
GlobeNewswire Direct company coverage

OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating Omeros Corporation (NASDAQ: OMER) on behalf of investors for potential securities law violations. This follows Omeros's announcement on June 26, 2026, that the European Medicines Agency's CHMP issued a negative opinion on its marketing authori

Tone
Negative 28/100
Event
Regulatory and legal
Published
08 Jul 2026 19:39
Source
GlobeNewswire
Pluang Direct company coverage

Omeros shares drop 19% after EMA rejects narsoplimab drug approval, triggering fraud probe.

Shares of Omeros Corporation dropped over 19% after the European Medicines Agency's CHMP issued a negative opinion on its marketing authorization application for narsoplimab, a TA-TMA treatment. This rejection has prompted The Schall Law Firm to launch an investigation into wheth

Tone
Negative 8/100
Event
Regulatory and legal
Published
08 Jul 2026 17:11
Source
Pluang
ACCESS Newswire Direct company coverage

Omeros Corporation (OMER) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Omeros Corporation (NASDAQ:OMER) purchasers following a significant drop in its stock price. This decline occurred after the Committee for Medicinal Products for Human Use (CHMP) of the European Med

Tone
Negative 26/100
Event
Regulatory and legal
Published
08 Jul 2026 06:41
Source
ACCESS Newswire
Caledonian Record Direct company coverage

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros ...

Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation (NASDAQ: OMER) following a significant stock price drop. The investigation stems from Omeros announcing that the European Medicines Agency's Committee for Medicinal Products for Human Use

Tone
Negative 15/100
Event
Regulatory and legal
Published
07 Jul 2026 22:09
Source
Caledonian Record
Market source Direct company coverage

Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now?

Omeros Corporation (OMER) is highlighted as a top "get rich quick" stock despite a recent price target trim by H.C. Wainwright due to a "disappointing" CHMP opinion for Yartemlea. The analyst still maintains a Buy rating, viewing the U.S. Yartemlea launch as a key value driver. O

Tone
Positive 63/100
Event
Analyst action
Published
07 Jul 2026 05:53
Source
Market source
Minichart Direct company coverage

Omeros Corporation Files SEC Form 8-K for Other Events – Nasdaq: OMER, July 2026

Omeros Corporation has filed an SEC Form 8-K announcing the repurchase of a significant portion of its 9.50% Convertible Senior Notes due 2029. The company plans to repurchase an initial $16.0 million for approximately $31.3 million and potentially an additional $14.5 million, re

Tone
Positive 71/100
Event
Capital return
Published
06 Jul 2026 14:37
Source
Minichart
Stock Titan Direct company coverage

Omeros (NASDAQ: OMER) expands 2029 note repurchases and weighs new debt

Omeros Corporation is repurchasing a significant portion of its 9.50% Convertible Senior Notes due 2029 to reduce costly debt. The company expects to complete an initial repurchase of $16.0 million in principal, leaving $54.8 million outstanding, and has agreed to repurchase an a

Tone
Neutral 50/100
Event
Guidance
Published
06 Jul 2026 12:11
Source
Stock Titan
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Omeros Corporation (OMER) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Omeros Corporation (OMER) following a significant stock price drop. The investigation comes after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative o

Tone
Negative 25/100
Event
Regulatory and legal
Published
05 Jul 2026 18:40
Source
ACCESS Newswire
TradingView Direct company coverage

Enterprise value to revenue forward of Omeros Corporation – NASDAQ:OMER

This article provides financial information for Omeros Corporation (NASDAQ: OMER), specifically focusing on its enterprise value to revenue forward metric. The content appears to be a stub or a section of a larger financial data page, showing a table header for "Period," "Value,"

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 06:11
Source
TradingView
The National Law Review Direct company coverage

Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation announced its first-quarter 2026 financial results, reporting net income of $56.1 million, or $0.78 per share, a significant improvement from a net loss in the prior year. This turnaround was driven by the commercial launch of YARTEMLEA® in January 2026, which

Tone
Positive 72/100
Event
Earnings
Published
04 Jul 2026 07:10
Source
The National Law Review
PR Newswire Direct company coverage

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation (NASDAQ: OMER) following a significant stock price drop. The investigation began after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negati

Tone
Negative 13/100
Event
Regulatory and legal
Published
02 Jul 2026 00:10
Source
PR Newswire
Pluang Direct company coverage

Omeros stock drops 19% after EU rejects key drug application, prompting fraud investigation

Omeros Corporation's stock dropped 19.12% after the European Medicines Agency's committee issued a negative opinion on its drug narsoplimab. This rejection led to an investigation by Pomerantz LLP into potential securities fraud against Omeros and its executives. The development

Tone
Negative 9/100
Event
Regulatory and legal
Published
02 Jul 2026 00:10
Source
Pluang
TradingView Direct company coverage

Price to earnings forward of Omeros Corporation – NASDAQ:OMER

This article provides financial information for Omeros Corporation (NASDAQ: OMER), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication, with no trades recorded. The content is presented within the contex

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 14:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Omeros Corporation – BX:3O8

The article focuses on the "Price to earnings forward" metric for Omeros Corporation (BX:3O8), listed on BX Swiss. It presents an overview of financial data for the company, indicating that the market was closed at the time of publication with no trades.

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 10:40
Source
TradingView
Sahm Direct company coverage

FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide

Omeros Corporation's narsoplimab, branded as Yartemlea, received a negative opinion from the European Medicines Agency's Human Medicines Committee (CHMP) for its stem cell transplant-associated thrombotic microangiopathy treatment. This contrasts with its approval by the U.S. FDA

Tone
Negative 29/100
Event
Regulatory and legal
Published
28 Jun 2026 03:39
Source
Sahm
TradingView Direct company coverage

Enterprise value to EBITDA forward of Omeros Corporation – NASDAQ:OMER

This article focuses on the enterprise value to EBITDA forward metric for Omeros Corporation (NASDAQ: OMER). It is a financial data point presented within the context of a market analysis platform, likely TradingView, indicating a key valuation ratio for the pharmaceutical compan

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 02:36
Source
TradingView
TradingView Direct company coverage

Price to book forward of Omeros Corporation – BX:3O8

This page from TradingView provides financial information for Omeros Corporation (BX:3O8), specifically focusing on its price-to-book forward ratio. It highlights that the market for this stock is currently closed with no trades. The site also lists various tools and services off

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 00:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Omeros Corporation – NASDAQ:OMER

The article provides a financial overview of Omeros Corporation (NASDAQ: OMER), specifically focusing on its Price to Sales (forward) metric. It mentions the stock is listed on Nasdaq and that the market was closed at the time of publication, with no trades. The content is primar

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 05:08
Source
TradingView
Investing.com Direct company coverage

European regulator issues negative opinion on Omeros’ TA-TMA drug

The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a negative opinion on Omeros Corporation's marketing authorization application for narsoplimab, a drug to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-T

Tone
Negative 30/100
Event
Market update
Published
26 Jun 2026 14:40
Source
Investing.com
BioSpace Direct company coverage

Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros Corporation announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its marketing authorization application for narsoplimab (YARTEMLEA®) for treating hematopoietic stem cell transplant-associat

Tone
Negative 36/100
Event
Market update
Published
26 Jun 2026 13:40
Source
BioSpace
Seeking Alpha Direct company coverage

Omeros drops amid EU hurdle for transplant drug (OMER:NASDAQ)

Omeros (OMER) shares dropped significantly in premarket trading after an expert panel of the EU drug regulator, the European Medicines Agency, declined to endorse the company's transplant therapy, narsoplimab. The Seattle-based biotech company released a statement regarding this

Tone
Negative 20/100
Event
Market update
Published
26 Jun 2026 12:54
Source
Seeking Alpha
Investing.com Direct company coverage

Omeros stock tumbles after EMA panel rejects narsoplimab application

Omeros Corporation shares fell significantly after a European Medicines Agency (EMA) panel issued a negative opinion on its marketing authorization application for narsoplimab, a drug for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Despite t

Tone
Negative 27/100
Event
Market update
Published
26 Jun 2026 12:40
Source
Investing.com